| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
12.90(B) |
| Last
Volume: |
408,164 |
Avg
Vol: |
421,328 |
| 52
Week Range: |
$205.19 - $276.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
577,395 |
619,080 |
681,963 |
1,862,458 |
| Total Sell Value |
$140,716,560 |
$150,163,103 |
$164,291,315 |
$457,286,236 |
| Total People Sold |
8 |
8 |
8 |
11 |
| Total Sell Transactions |
69 |
79 |
91 |
266 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-10-20 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,397 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-10-06 |
4 |
AS |
$208.94 |
$1,255,561 |
D/D |
(6,000) |
36,397 |
|
22% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-10-06 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,397 |
|
- |
|
| Sullivan Louis |
|
– • – |
2022-10-03 |
4 |
AS |
$211.56 |
$150,208 |
D/D |
(710) |
12,180 |
|
18% |
|
| Sullivan Louis |
|
– • – |
2022-10-03 |
4 |
OE |
$132.30 |
$93,933 |
D/D |
710 |
12,890 |
|
- |
|
| Mesa Nilda |
|
– • – |
2022-09-29 |
4 |
S |
$207.36 |
$82,943 |
D/D |
(400) |
6,470 |
|
-23% |
|
| Mesa Nilda |
|
– • – |
2022-09-28 |
4 |
S |
$211.05 |
$179,391 |
D/D |
(850) |
6,870 |
|
-20% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-09-22 |
4 |
AS |
$202.46 |
$1,220,048 |
D/D |
(6,000) |
36,397 |
|
22% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-09-22 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,397 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-09-09 |
4 |
D |
$223.48 |
$670,440 |
D/D |
(3,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-09-09 |
4 |
OE |
$63.90 |
$191,700 |
D/D |
3,000 |
3,000 |
|
- |
|
| Sullivan Louis |
|
– • – |
2022-09-02 |
4 |
S |
$225.98 |
$1,109,550 |
D/D |
(4,910) |
12,180 |
|
-17% |
|
| Sullivan Louis |
|
– • – |
2022-09-02 |
4 |
OE |
$101.80 |
$499,838 |
D/D |
4,910 |
17,090 |
|
- |
|
| Causey Christopher |
|
– • – |
2022-08-23 |
4 |
S |
$224.96 |
$787,360 |
D/D |
(3,500) |
2,835 |
|
-20% |
|
| Causey Christopher |
|
– • – |
2022-08-23 |
4 |
OE |
$175.43 |
$614,005 |
D/D |
3,500 |
6,335 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-08-17 |
4 |
D |
$221.63 |
$664,890 |
D/D |
(3,000) |
1,680 |
|
- |
|
| Patusky Christopher |
|
– • – |
2022-08-17 |
4 |
OE |
$63.90 |
$227,895 |
D/D |
3,000 |
3,180 |
|
- |
|
| Kurzweil Ray |
|
– • – |
2022-08-09 |
4 |
OE |
$219.17 |
$3,287,550 |
D/D |
15,000 |
10,300 |
|
- |
|
| Kurzweil Ray |
|
– • – |
2022-08-09 |
4 |
OE |
$63.90 |
$958,500 |
D/D |
15,000 |
25,300 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-08-04 |
4 |
AS |
$225.81 |
$1,027,887 |
D/D |
(4,552) |
36,397 |
|
25% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-08-04 |
4 |
OE |
$111.00 |
$505,272 |
D/D |
4,552 |
40,949 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-07-21 |
4 |
AS |
$224.67 |
$1,357,635 |
D/D |
(6,000) |
36,397 |
|
22% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-07-21 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,397 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-07-11 |
4 |
AS |
$241.29 |
$521,186 |
D/D |
(2,160) |
0 |
|
10% |
|
| Kurzweil Ray |
|
– • – |
2022-07-08 |
4/A |
OE |
$0.00 |
$0 |
D/D |
1,080 |
10,300 |
|
- |
|
5052 Records found
|
|
Page 23 of 203 |
|
|
3.62 (1.31%) 
